Projections of Healthcare Resource Utilization and Costs Related to Exacerbations for Budesonide/Glycopyrrolate/Formoterol Fumarate Versus Dual Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist and Inhaled Corticosteroid/Long-Acting β2-Agonist Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease

被引：0
|
作者：
De Nigris, E. [1 ]
Treharne, C. [2 ]
Brighton, N. [2 ]
Holmgren, U. [3 ]
Walker, A. [4 ]
Haughney, J. [5 ]
机构：
[1] AstraZeneca, Cambridge, England
[2] Parexel Int, London, England
[3] AstraZeneca, Gothenburg, Sweden
[4] Salus Alba, Glasgow, Lanark, Scotland
[5] Queen Elizabeth Univ Hosp, Clin Res Facil, Glasgow, Lanark, Scotland
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2021年 / 203卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2249
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Lifetime Benefits for Budesonide/Glycopyrrolate/Formoterol Fumarate versus Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist and Inhaled Corticosteroid/Long-Acting β2-Agonist Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease
    De Nigris, E.
    Treharne, C.
    Brighton, N.
    Holmgren, U.
    Walker, A.
    Haughney, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [2] Role of Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Therapy in Chronic Obstructive Pulmonary Disease
    Petite, Sarah E.
    ANNALS OF PHARMACOTHERAPY, 2017, 51 (08) : 696 - 705
  • [3] Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β2-agonist bronchodilators
    Skolnik, Neil S.
    Nguyen, Trang Susan
    Shrestha, Aarisha
    Ray, Riju
    Corbridge, Thomas C.
    Brunton, Stephen A.
    POSTGRADUATE MEDICINE, 2020, 132 (02) : 198 - 205
  • [4] Combination inhaled corticosteroid and long-acting β2-agonist use and severe asthma exacerbations
    Pedersen, Soren
    O'Byrne, Paul M.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (05) : 1280 - 1281
  • [5] Long-acting muscarinic antagonist versus long-acting β2 agonist/corticosteroid for moderate to severe chronic obstructive pulmonary disease patients: Exacerbation risk assessment
    Yang, Sheau-Ning
    Ko, Hsin-Kuo
    Hsiao, Yi-Han
    Su, Kang-Cheng
    Chang, Yuh-Lih
    Huang, Hsin-Yi
    Perng, Diahn-Warng
    Chung, Mei-Ing
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2019, 82 (06) : 488 - 494
  • [6] Long-acting muscarinic antagonist and long-acting beta 2-agonist therapy to optimize chronic obstructive pulmonary disease prior to lung cancer surgery
    Makino, Takashi
    Otsuka, Hajime
    Hata, Yoshinobu
    Koezuka, Satoshi
    Azuma, Yoko
    Isobe, Kazutoshi
    Sugino, Keishi
    Ebihara, Sitorlt
    Homma, Sakae
    Iyoda, Akira
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 8 (05) : 647 - 652
  • [7] Long-acting inhaled β2-agonist therapy in asthma
    Kips, JC
    Pauwels, RA
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 164 (06) : 923 - 932
  • [8] Comparative Effectiveness of Long-Acting Beta2-Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease
    Samp, Jennifer C.
    Joo, Min J.
    Schumock, Glen T.
    Calip, Gregory S.
    Pickard, A. Simon
    Lee, Todd A.
    PHARMACOTHERAPY, 2017, 37 (04): : 447 - 455
  • [9] Switching from long-acting beta-agonist and inhaled corticosteroid to long-acting beta-agonist and long-acting muscarinic antagonist for chronic obstructive pulmonary disease: a case report of inhaled corticosteroid withdrawal
    Lam, Jamie Chung Mei
    INTERNAL MEDICINE JOURNAL, 2020, 50 : 15 - 18
  • [10] Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting 2-Agonist Combined With a Long-Acting Muscarinic or Inhaled Corticosteroid
    Samp, Jennifer C.
    Joo, Min J.
    Schumock, Glen T.
    Calip, Gregory S.
    Pickard, A. Simon
    Lee, Todd A.
    ANNALS OF PHARMACOTHERAPY, 2017, 51 (11) : 945 - 953
12345